Advertisement
Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated (LGND) Stock Overview

Explore Ligand Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.

LGNDNASDAQ
HealthcareBiotechnology
$235.91
$1.51(0.64%)
U.S. Market opens in 14h 50m
Advertisement

Ligand Pharmaceuticals Incorporated (LGND)

Meyka AI Score

Z

Key Financials

Market Cap4.7B
P/E Ratio30.43
EPS (TTM)$7.67
ROE0.16%
Fundamental Analysis

AI Price Forecasts

1 Month$189.99
3 Months$199.93
1 Year Target$137.82

LGND Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Ligand Pharmaceuticals Incorporated (LGND) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 60.77, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $137.82.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 30.43 and a market capitalization of 4.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
0.64%
5-Day Change
0.48%
1-Month Change
3.31%
3-Month Change
12.90%
6-Month Change
25.15%
Year-to-Date (YTD) Change
24.77%
1-Year Change
127.27%
3-Year Change
232.27%
5-Year Change
227.74%
All-Time (Max) Change
414.53%

Contact Information

858 550 7500
5980 Horton Street, Jupiter, CA, 94608

Company Facts

68 Employees
IPO DateNov 18, 1992
CountryUS
Actively Trading

Frequently Asked Questions